


# Reference Data

(Consolidated Financial Results for Q3 FY2012)



Daiichi-Sankyo

January 31, 2013

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

# MEMO

(This page is intentionally left blank)

# Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Consolidated Balance Sheets	P8
8.	Consolidated Statements of Cash Flow	P10
9.	Summary of Product Outlines	P11
10.	Major R&D Pipeline (Innovative pharmaceuticals)	P12

Supplemental Information

Historical Data

## 1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			Q3 YTD					FY2012				
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to forecast	to sales	Forecast	from Oct	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>242.6</b>	<b>+4.7%</b>	<b>100%</b>	<b>241.6</b>	<b>+7.7%</b>	<b>100%</b>	<b>261.5</b>	<b>+8.8%</b>				<b>100%</b>	<b>745.6</b>	<b>49.2</b>	<b>+7.1%</b>	<b>75%</b>	<b>100%</b>	<b>990.0</b>	<b>10.0</b>	<b>51.3</b>	<b>+5.5%</b>
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%	33%	86.4	+20.6%				31%	230.2	29.7	+14.8%	75%	31%	307.0	5.0	38.4	+14.3%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%	67%	175.1	+3.8%				69%	515.4	19.5	+3.9%	75%	69%	683.0	5.0	12.9	+1.9%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%	53%	138.6	-0.3%				57%	421.9	17.9	+4.4%	72%	59%	583.0	5.0	11.1	+1.9%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%	17%	44.6	-0.3%				18%	131.8	3.0	+2.4%	70%	19%	188.0	0.0	2.9	+1.6%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%	10%	25.3	+2.0%				9%	69.6	0.4	+0.5%			not disclosed			
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%	13%	34.1	+1.2%				14%	103.0	-1.2	-1.2%			not disclosed			
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%	13%	34.6	-3.2%				16%	117.4	15.7	+15.4%			not disclosed			
<b>Operating Income</b>	<b>13%</b>	<b>32.5</b>	<b>-25.2%</b>	<b>10%</b>	<b>24.6</b>	<b>+31.2%</b>	<b>14%</b>	<b>36.5</b>	<b>+22.9%</b>				<b>13%</b>	<b>93.5</b>	<b>1.7</b>	<b>+1.8%</b>	<b>94%</b>	<b>10%</b>	<b>100.0</b>	<b>0.0</b>	<b>1.8</b>	<b>+1.8%</b>
Non-operating income / expenses		8.3			-15.5			9.4						2.1	7.6				-5.0	-5.0	17.0	
Non-operating income		10.3			-5.3			8.1						13.1	4.8				not disclosed			
Non-operating expenses		2.0			10.2			-1.2						11.0	-2.8				not disclosed			
<b>Ordinary Income</b>	<b>17%</b>	<b>40.8</b>	<b>-9.0%</b>	<b>4%</b>	<b>9.0</b>	<b>-58.0%</b>	<b>18%</b>	<b>45.8</b>	<b>+128.3%</b>				<b>13%</b>	<b>95.7</b>	<b>9.3</b>	<b>+10.7%</b>	<b>101%</b>	<b>10%</b>	<b>95.0</b>	<b>-5.0</b>	<b>18.8</b>	<b>+24.6%</b>
Extraordinary income / losses		0.6			-5.2			-5.7						-10.3	35.7				-10.0	-5.0	32.3	
Extraordinary income		2.0			0.5			0.7						3.2	1.1				not disclosed			
Extraordinary losses		1.5			5.7			6.4						13.5	-34.6				not disclosed			
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%	15%	40.2	-				11%	85.4	45.0	+111.3%	100%	9%	85.0	-10.0	51.1	+150.6%
Income taxes / minority interests		21.0			-0.1			13.0						33.9	11.0				35.0	-10.0	11.5	
Income taxes		16.8			3.0			10.2						29.9	-8.0				not disclosed			
Minority interests		4.2			-3.1			2.8						3.9	19.0				not disclosed			
<b>Net Income</b>	<b>8%</b>	<b>20.4</b>	<b>-19.4%</b>	<b>2%</b>	<b>4.0</b>	<b>-66.3%</b>	<b>10%</b>	<b>27.1</b>	<b>-</b>				<b>7%</b>	<b>51.5</b>	<b>34.0</b>	<b>+193.6%</b>	<b>103%</b>	<b>5%</b>	<b>50.0</b>	<b>0.0</b>	<b>39.6</b>	<b>+381.6%</b>
Effective tax rate		41%			78%			25%						35%								
Overseas sales ratio results		54%			48%			44%						49%								

### Notes to FY2012 Q3 Results Year-on-Year Comparisons

Net Sales	{	Ranbaxy +31.2 (appreciation of JPY to INR -28.0), Memyary +10.7, Nexium +9.5, Prasugrel alliance revenue +3.1, Ranmark +3.0
SG&A expenses	{	Mevalotin -6.4, Luitpold -6.7, Levofloxacin export, royalty, etc -3.0
		R&D: Forex impact (appreciation of JPY to USD, EUR, and INR) -1.0
		Other: Forex impact (appreciation of JPY to USD, EUR, and INR) -13.0
Non-operating items		"Forex gains" and "gain on valuation of derivatives" of Ranbaxy
Extraordinary losses	{	Loss on impairment of long-lived assets +8.3
Income Taxes	{	FY2011 Q3: Tax rate worsened by special factors; Reversal in deferred tax asset following the cut in income tax rate in Japan, Provision for settlement expenses not tax deductible
		FY2012 Q3: Tax rate improved by deferred tax asset since accumulated losses were cleared

### Notes to Revision in FY2012 Forecast

Net Sales	Contribution of sales increase in DSI, partially off set by sales decrease in Japan and LPI
Non-operating items	Loss following the appreciation of INR to USD
Extraordinary Items	Loss on impairment of long-lived assets

## 2. Currency Rate

	Q1		Q2 YTD		Q3 YTD		Q4 YTD		Q3 YTD		FY2012	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Forecast	from Dec
USD/JPY (average)	80.21		79.42		80.01		80.01	+1.01	80.01	+1.01	81.26	1.26
EUR/JPY (average)	102.91		100.64		102.18		102.18	-8.44	102.18	-8.44	105.39	5.39
INR/JPY (average)	1.59		1.54		1.50		1.50	-0.29	1.50	-0.29	-	-

Appreciation of JPY to USD, EUR, and INR negatively affected the FY2012 Q3 results by 30 bil yen in net sales and 4.0 bil yen in operating income. Annual impact of one yen change is estimated to affect the group's FY2012 performance by; USD: net sales 2 bil yen, operating income minor / EUR: net sales 0.7 bil yen, operating income minor

\*Q4 Forecast: USD/JPY 85.00  
EUR/JPY 115.00

### 3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			Q3 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%		223.1	+9.0%					600.6	18.0	+3.1%
Inter-segment sales		0.3			0.3			0.7						1.3	0.8	
<b>Net sales</b>	<b>100%</b>	<b>183.8</b>	<b>-4.2%</b>	<b>100%</b>	<b>194.2</b>	<b>+4.4%</b>	<b>100%</b>	<b>223.8</b>	<b>+9.2%</b>				<b>100%</b>	<b>601.9</b>	<b>18.8</b>	<b>+3.2%</b>
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%	30%	67.3	+28.1%				29%	171.3	29.3	+20.6%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%	70%	156.5	+2.6%				72%	430.6	-10.5	-2.4%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%	54%	121.8	-0.4%				59%	355.5	2.8	+0.8%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%	19%	42.8	+0.2%				21%	126.3	3.5	+2.9%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%	35%	79.0	-0.8%				38%	229.2	-0.7	-0.3%
<b>Operating Income</b>	<b>11%</b>	<b>20.1</b>	<b>-49.3%</b>	<b>10%</b>	<b>20.3</b>	<b>+8.9%</b>	<b>16%</b>	<b>34.7</b>	<b>+15.1%</b>				<b>13%</b>	<b>75.1</b>	<b>-13.3</b>	<b>-15.1%</b>
Non-operating income		2.1			1.0			2.5						5.6	-1.4	
Non-operating expenses		1.0			1.6			1.2						3.8	-0.1	
<b>Ordinary Income</b>	<b>11%</b>	<b>21.1</b>	<b>-49.2%</b>	<b>10%</b>	<b>19.8</b>	<b>+4.2%</b>	<b>16%</b>	<b>36.1</b>	<b>+16.1%</b>				<b>13%</b>	<b>76.9</b>	<b>-14.7</b>	<b>-16.0%</b>
Extraordinary income		2.0			0.4			0.6						3.1	1.2	
Extraordinary losses		1.3			5.7			6.3						13.4	5.7	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%	14%	30.4	+2.8%				11%	66.6	-19.2	-22.3%
Income taxes		8.1			4.4			6.9						19.4	-23.3	
Minority interests		-0.1			-0.0			0.2						0.1	1.6	
<b>Net Income</b>	<b>7%</b>	<b>13.7</b>	<b>-40.1%</b>	<b>5%</b>	<b>10.2</b>	<b>-4.6%</b>	<b>10%</b>	<b>23.2</b>	<b>+110.3%</b>				<b>8%</b>	<b>47.1</b>	<b>2.5</b>	<b>+5.7%</b>

Ranbaxy Group		Q1			Q2			Q3			Q4			Q3 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	
Sales to outside customers		59.1	+48.7%		47.6	+24.0%		38.3	+7.5%					145.1	31.2	+27.4%	
Inter-segment sales		0.7			0.3			0.3						1.3	0.6		
<b>Net sales</b>	<b>100%</b>	<b>59.8</b>	<b>+49.5%</b>	<b>100%</b>	<b>47.9</b>	<b>+24.1%</b>	<b>100%</b>	<b>38.6</b>	<b>+7.5%</b>				<b>100%</b>	<b>146.3</b>	<b>31.8</b>	<b>+27.8%</b>	
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%	52%	20.1	+3.0%				42%	61.0	2.0	+3.5%	
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%	48%	18.5	+12.9%				58%	85.3	29.8	+53.6%	
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%	41%	15.7	+0.5%				43%	63.0	15.2	+31.9%	
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%	5%	1.9	-17.0%				4%	6.1	-0.9	-13.3%	
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%	36%	13.8	+3.6%				39%	57.0	16.2	+39.6%	
<b>Operating Income</b>	<b>23%</b>	<b>13.8</b>	<b>+161.9%</b>	<b>12%</b>	<b>5.6</b>	<b>+238.2%</b>	<b>7%</b>	<b>2.9</b>	<b>+238.4%</b>				<b>15%</b>	<b>22.3</b>	<b>14.5</b>	<b>+186.5%</b>	
Non-operating income		8.3			-6.2			5.7						7.7	5.3		
Non-operating expenses		0.8			8.6			-2.5						7.0	-2.7		
<b>Ordinary Income</b>	<b>36%</b>	<b>21.2</b>	<b>+269.3%</b>	<b>-19%</b>	<b>-9.2</b>	<b>-317.5%</b>	<b>29%</b>	<b>11.0</b>	<b>-215.8%</b>				<b>16%</b>	<b>23.0</b>	<b>22.5</b>	<b>+4630.8%</b>	
Extraordinary income		0.0			0.0			0.0						0.1	-0.8		
Extraordinary losses		0.1			-0.0			0.0						0.2	0.0		
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%	29%	11.0	-226.6%				16%	23.0	21.8	+1837.3%	
Income taxes		6.1			-2.3			3.6						7.3	11.0		
Minority interests		0.0			0.0			0.1						0.1	0.0		
<b>Net Income</b>	<b>25%</b>	<b>15.0</b>	<b>+118.9%</b>	<b>-14%</b>	<b>-6.9</b>	<b>-297.1%</b>	<b>19%</b>	<b>7.4</b>	<b>-231.8%</b>				<b>11%</b>	<b>15.5</b>	<b>10.8</b>	<b>+227.3%</b>	

#### Inter-segment Transactions

<b>Net sales</b>		<b>-1.0</b>			<b>-0.6</b>			<b>-1.0</b>						<b>-2.6</b>		
Cost of sales		-0.7			-0.4			-0.9						-2.0		
Gross Profit		-0.3			-0.2			-0.0						-0.5		
SG&A expenses		1.1			1.2			1.1						3.4		
R&D expenses		-0.3			-0.1			-0.1						-0.5		
Other expenses		1.4			1.3			1.3						3.9		
<b>Operating Income</b>		<b>-1.4</b>			<b>-1.4</b>			<b>-1.1</b>						<b>-3.9</b>		
Non-operating income		-0.0			-0.1			-0.1						-0.2		
Non-operating expenses		0.1			0.0			0.0						0.2		
<b>Ordinary Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.2</b>						<b>-4.3</b>		
Extraordinary income		-			0.0			0.0						0.0		
Extraordinary losses		0.0			-0.0			0.0						0.0		
Income before income taxes and minority interests		-1.5			-1.5			-1.2						-4.2		
Income taxes		2.6			0.9			-0.3						3.2		
Minority interests		4.2			-3.1			2.6						3.7		
<b>Net Income</b>		<b>-8.3</b>			<b>0.7</b>			<b>-3.5</b>						<b>-11.1</b>		

#### 4. Sales by Business Units

	FY2012			Q1			Q2			Q3			Q4			Q3 YTD			
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan*1	Results	YoY	to plan*1	Results	YoY	to plan*1	Results	YoY	to plan	Results	YoY	YoY	to plan*1
JPY Bn																			
<b>Consolidated Net Sales</b>	<b>980.0</b>	<b>990.0</b>	<b>10.0</b>	<b>242.6</b>	<b>+4.7%</b>	<b>25%</b>	<b>241.6</b>	<b>+7.7%</b>	<b>24%</b>	<b>261.5</b>	<b>+8.8%</b>	<b>26%</b>				<b>745.6</b>	<b>49.2</b>	<b>+7.1%</b>	<b>75%</b>
<b>Japan Company (domestic sales)</b>	<b>450.0</b>	<b>440.0</b>	<b>-10.0</b>	<b>98.2</b>	<b>-2.2%</b>	<b>22%</b>	<b>106.9</b>	<b>+6.3%</b>	<b>24%</b>	<b>124.7</b>	<b>+9.5%</b>	<b>28%</b>				<b>329.8</b>	<b>14.9</b>	<b>+4.7%</b>	<b>75%</b>
Olmotec	81.0	76.0	-5.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%				58.5	-5.0	-7.9%	77%
Rezaltas	19.0	16.0	-3.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%				12.6	2.7	+27.5%	79%
Calblock	13.0	10.0	-3.0	2.7	-14.0%	27%	2.8	-12.9%	28%	2.8	-13.8%	28%				8.4	-1.3	-13.5%	84%
Loxonin	62.0	60.0	-2.0	14.1	-2.0%	24%	15.6	-0.4%	26%	16.2	-6.1%	27%				45.9	-1.4	-3.0%	77%
Cravit	37.0	35.0	-2.0	8.1	-4.2%	23%	8.4	+0.0%	24%	10.6	-2.0%	30%				27.1	-0.6	-2.0%	78%
Nexium	29.0	22.0	-7.0	1.7	-	8%	2.7	+7.1%	13%	8.3	+1254.8%	38%				12.7	9.5	+299.7%	58%
Memyary	26.0	26.0	0.0	5.1	+128.7%	20%	5.6	+247.5%	22%	6.6	+135.7%	25%				17.4	10.7	+160.6%	67%
Mevalotin	26.0	26.0	0.0	6.5	-25.7%	25%	6.8	-21.8%	26%	6.6	-25.6%	25%				19.9	-6.4	-24.4%	76%
Artist	21.0	22.0	1.0	5.6	-8.9%	25%	5.6	-9.3%	26%	5.8	-10.9%	27%				17.1	-1.8	-9.7%	78%
Omnipaque	18.0	20.0	2.0	4.9	-13.2%	25%	5.3	-15.9%	26%	5.4	-16.3%	27%				15.5	-2.8	-15.2%	78%
Urief	11.0	11.0	0.0	2.7	+0.5%	24%	2.8	+0.1%	25%	3.0	-1.8%	27%				8.4	0.0	-0.5%	76%
Inavir	10.0	11.0	1.0	0.4	+10.3%	4%	0.1	-164.9%	1%	2.1	+22.9%	19%				2.6	0.6	+29.1%	23%
Ranmark	5.0	5.0	0.0	0.6	-	12%	1.1	-	22%	1.3	-	27%				3.0	3.0	-	61%
Vaccines	not disclosed	not disclosed	-	5.2	+13.9%	-	8.1	+52.5%	-	11.8	+72.2%	-				25.1	8.4	+50.1%	-
Daiichi Sankyo Espha products	not disclosed	not disclosed	-	2.8	+16.2%	-	2.7	+12.7%	-	3.0	+2.4%	-				8.5	0.8	+9.9%	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>48.0</b>	<b>48.0</b>	<b>0.0</b>	<b>10.2</b>	<b>+5.0%</b>	<b>21%</b>	<b>12.8</b>	<b>+1.1%</b>	<b>27%</b>	<b>14.5</b>	<b>+6.1%</b>	<b>30%</b>				<b>37.6</b>	<b>1.5</b>	<b>+4.0%</b>	<b>78%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>115.0</b>	<b>139.0</b>	<b>24.0</b>	<b>35.9</b>	<b>+3.7%</b>	<b>26%</b>	<b>32.6</b>	<b>+10.0%</b>	<b>24%</b>	<b>37.4</b>	<b>+23.9%</b>	<b>27%</b>				<b>105.9</b>	<b>11.5</b>	<b>+12.1%</b>	<b>76%</b>
Olmesartan	71.0	93.0	22.0	23.9	-3.8%	26%	21.7	+6.3%	23%	25.7	+24.9%	28%				71.3	5.4	+8.3%	77%
Benicar/Benicar HCT	54.0	73.0	19.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%				55.8	2.7	+5.0%	77%
Azor	11.0	14.0	3.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%				10.8	1.6	+17.3%	77%
Tribenzor	6.0	6.0	0.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%				4.7	1.2	+34.1%	78%
Welchol	31.0	31.0	0.0	8.3	+17.5%	27%	7.2	+10.5%	23%	8.3	+26.1%	27%				23.8	3.6	+18.1%	77%
Effient (alliance revenue)	not disclosed	not disclosed	-	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-				7.5	2.3	+45.1%	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>44.0</b>	<b>38.0</b>	<b>-6.0</b>	<b>11.3</b>	<b>-10.9%</b>	<b>30%</b>	<b>7.7</b>	<b>-17.4%</b>	<b>20%</b>	<b>11.3</b>	<b>-24.7%</b>	<b>30%</b>				<b>30.4</b>	<b>-6.7</b>	<b>-18.1%</b>	<b>80%</b>
Venofer	23.0	23.0	0.0	6.8	-7.4%	30%	3.8	-30.4%	17%	8.3	-8.5%	36%				19.0	-3.0	-13.6%	82%
<b>Daiichi Sankyo Europe GmbH</b>	<b>65.0</b>	<b>65.0</b>	<b>0.0</b>	<b>13.9</b>	<b>-17.6%</b>	<b>21%</b>	<b>15.1</b>	<b>-10.8%</b>	<b>23%</b>	<b>16.9</b>	<b>-2.6%</b>	<b>26%</b>				<b>45.9</b>	<b>-5.2</b>	<b>-10.3%</b>	<b>71%</b>
Olmesartan	48.0	48.0	0.0	9.9	-16.6%	21%	11.3	-6.6%	24%	12.9	+1.8%	27%				34.1	-2.6	-7.0%	71%
Olmotec/Olmotec Plus	34.0	34.0	0.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%				23.1	-3.6	-13.5%	68%
Sevikar	10.0	10.0	0.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%				7.9	0.2	+3.2%	79%
Sevikar HCT	4.0	4.0	0.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%				3.1	0.8	+35.8%	79%
Effient (alliance revenue)	not disclosed	not disclosed	-	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-				2.7	0.8	+42.0%	-

	FY2012			Q1			Q2			Q3			Q4			Q3 YTD			
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan*1	Results	YoY	to plan*1	Results	YoY	to plan*1	Results	YoY	to plan	Results	YoY	YoY	to plan*1
<b>Asia, South and Central America (ASCA)<sup>2</sup></b>	<b>38.0</b>	<b>38.0</b>	<b>0.0</b>	<b>7.1</b>	<b>+9.8%</b>	<b>19%</b>	<b>8.1</b>	<b>+10.1%</b>	<b>21%</b>	<b>8.2</b>	<b>+18.4%</b>	<b>22%</b>				<b>23.4</b>	<b>2.6</b>	<b>+12.8%</b>	<b>62%</b>
Daiichi Sankyo China <sup>3</sup>	not disclosed	not disclosed	-	2.7	+0.9%	-	3.0	+16.0%	-	3.1	+50.9%	-				8.8	4.1	+87.3%	-
Daiichi Sankyo Taiwan	not disclosed	not disclosed	-	0.8	-5.9%	-	0.8	-1.3%	-	0.8	+7.8%	-				2.4	0.0	+0.0%	-
Daiichi Sankyo Korea	not disclosed	not disclosed	-	1.2	+2.1%	-	1.2	+5.5%	-	1.3	+16.8%	-				3.8	0.3	+8.0%	-
Daiichi Sankyo (Thailand)	not disclosed	not disclosed	-	0.3	+3.7%	-	0.3	+2.7%	-	0.4	+14.5%	-				0.9	0.1	+7.3%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	not disclosed	-	1.2	+14.2%	-	1.2	-22.5%	-	1.0	-34.4%	-				3.4	-0.7	-17.4%	-
Daiichi Sankyo Venezuela	not disclosed	not disclosed	-	0.8	+87.0%	-	1.4	+49.5%	-	1.5	+37.1%	-				3.8	1.3	+50.8%	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	not disclosed	-	0.1	-	-	0.1	-	-	0.1	-	-				0.3	0.2	-	-
<b>Ranbaxy Laboratories Limited</b>	<b>179.0</b>	<b>179.0</b>	<b>0.0</b>	<b>59.1</b>	<b>+48.7%</b>	<b>33%</b>	<b>47.6</b>	<b>+24.0%</b>	<b>27%</b>	<b>38.3</b>	<b>+7.5%</b>	<b>21%</b>				<b>145.1</b>	<b>31.2</b>	<b>+27.4%</b>	<b>81%</b>
<b>Others</b>	<b>41.0</b>	<b>43.0</b>	<b>2.0</b>	<b>6.8</b>	<b>-38.0%</b>	<b>16%</b>	<b>10.7</b>	<b>+13.1%</b>	<b>25%</b>	<b>10.0</b>	<b>+32.8%</b>	<b>23%</b>				<b>27.6</b>	<b>-0.5</b>	<b>-1.7%</b>	<b>64%</b>
Levofloxacin export, royalty, etc	3.0	3.0	0.0	1.2	-60.1%	41%	1.0	-56.6%	34%	1.4	+19.3%	46%				3.6	-3.0	-45.0%	121%
Plexikon	not disclosed	not disclosed	-	0.1	-96.1%	-	1.4	-24.6%	-	1.0	+313.4%	-				2.6	-2.5	-49.5%	-

Currency rates for overseas subsidiaries

	Plan(May)	Plan(Jan)	Q1 Results	Q2 YTD Results	Q3 YTD Results	Q4 YTD Results	Q3 YTD Results
USD/JPY (average)	80.00 →	81.26	80.21	79.42	80.01		80.01
EUR/JPY (average)	100.00 →	105.39	102.91	100.64	102.18		102.18
INR/JPY (average)	-	-	1.59	1.54	1.50		1.50

New Product Launches

Apr 2012: Ranmark (anti-RANKL antibody for the treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors) launched in Japan.

Sep 2012: Tenelia ( DPP-4 inhibitor for the treatment of type 2 diabetes mellitus ) launched in Japan. □

Notes

\*1 Percentage achievement of Updated (Jan) plan

\*2 Since companies in China, Brazil, Venezuela and Mexico will change their fiscal year-ends from December to March, their FY2012 financial results will be for 15 months.

\*3 Daiichi Sankyo Pharmaceutical (Beijing) and Daiichi Sankyo Pharmaceutical (Shanghai) are consolidated as Daiichi Sankyo China.

**[Reference] Sales in Local Currency**

	FY2012			Q1			Q2			Q3			Q4			Q3 YTD			
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																			
<b>Daiichi Sankyo, Inc. (US)</b>	<b>1,438</b>	<b>1,711</b>	<b>273</b>	<b>448</b>	<b>+5.7%</b>	<b>26%</b>	<b>415</b>	<b>+8.7%</b>	<b>24%</b>	<b>461.0</b>	<b>+18.2%</b>	<b>27%</b>				<b>1,324</b>	<b>128</b>	<b>+10.7%</b>	<b>77%</b>
Olmesartan	888	1,144	257	298	-2.0%	26%	276	+4.9%	24%	317	+19.0%	28%				891	57	+6.9%	78%
Benicar/Benicar HCT	675	898	223	235	-4.5%	26%	213	-1.8%	24%	249	+18.8%	28%				698	25	+3.7%	78%
Azor	138	172	35	44	+0.2%	25%	44	+37.4%	26%	47	+15.5%	27%				135	18	+15.8%	78%
Tribenzor	75	75	0	19	+33.3%	26%	19	+33.0%	26%	20	+30.9%	27%				59	14	+32.4%	78%
Welchol	388	388	0	103	+19.7%	27%	92	+9.5%	24%	103	+20.3%	27%				298	42	+16.6%	77%
Effient (alliance revenue)	not disclosed	not disclosed	-	30	+54.7%	-	30	+35.4%	-	34	+41.2%	-				94	28	+43.3%	-
USD Mn																			
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>550</b>	<b>468</b>	<b>-82</b>	<b>141</b>	<b>-9.2%</b>	<b>30%</b>	<b>98</b>	<b>-18.5%</b>	<b>21%</b>	<b>140.0</b>	<b>-27.6%</b>	<b>30%</b>				<b>380</b>	<b>-90</b>	<b>-19.1%</b>	<b>81%</b>
Venofor	288	288	0	85	-5.6%	30%	49	-31.0%	17%	103	-11.8%	36%				237	-41	-14.7%	82%
EUR Mn																			
<b>Daiichi Sankyo Europe GmbH</b>	<b>650</b>	<b>650</b>	<b>0</b>	<b>135</b>	<b>-6.0%</b>	<b>21%</b>	<b>153</b>	<b>-0.2%</b>	<b>24%</b>	<b>161.0</b>	<b>-2.6%</b>	<b>25%</b>				<b>449</b>	<b>-13</b>	<b>-2.8%</b>	<b>69%</b>
Olmesartan	480	480	0	96	-4.8%	20%	115	+4.4%	24%	123	+2.0%	26%				334	2	+0.7%	70%
Olmetec/Olmetec Plus	340	340	0	62	-16.2%	18%	82	+3.1%	24%	82	-6.8%	24%				226	-15	-6.4%	67%
Sevikar	100	100	0	24	+19.3%	25%	23	-1.1%	24%	29	+17.7%	29%				77	8	+11.7%	77%
Sevikar HCT	40	40	0	9	+50.1%	24%	9	+41.0%	23%	12	+49.4%	30%				31	10	+47.0%	77%
Effient (alliance revenue)	not disclosed	not disclosed	-	9	+76.5%	-	9	+57.9%	-	9	+33.5%	-				27	9	+53.8%	-
INR Bn																			
<b>Ranbaxy Laboratories Limited</b>	<b>105</b>	<b>105</b>	<b>0</b>	<b>37</b>	<b>+71.1%</b>	<b>35%</b>	<b>32</b>	<b>+53.1%</b>	<b>31%</b>	<b>27.0</b>	<b>+31.2%</b>	<b>26%</b>				<b>97</b>	<b>33</b>	<b>+52.1%</b>	<b>92%</b>



## 5. Sales of Global Products

	FY2012			Q1			Q2			Q3			Q4			Q3 YTD			
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																			
<b>Olmесartan</b>	<b>237.0</b>	<b>251.0</b>	<b>14.0</b>	<b>60.0</b>	<b>-5.3%</b>	<b>24%</b>	<b>60.8</b>	<b>+0.6%</b>	<b>24%</b>	<b>68.2</b>	<b>+6.2%</b>	<b>27%</b>				<b>189.0</b>	<b>1.0</b>	<b>+0.5%</b>	<b>75%</b>
Olmotec (JPN)	81.0	76.0	-5.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%				58.5	-5.0	-7.9%	77%
Rezaltas (JPN)	19.0	16.0	-3.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%				12.6	2.7	+27.5%	79%
Benicar/Benicar HCT (US)	54.0	73.0	19.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%				55.8	2.7	+5.0%	77%
Azor (US)	11.0	14.0	3.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%				10.8	1.6	+17.3%	77%
Tribenzor (US)	6.0	6.0	0.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%				4.7	1.2	+34.1%	78%
Olmotec/Olmotec Plus (EU)	34.0	34.0	0.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%				23.1	-3.6	-13.5%	68%
Sevikar (EU)	10.0	10.0	0.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%				7.9	0.2	+3.2%	79%
Sevikar HCT (EU)	4.0	4.0	0.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%				3.1	0.8	+35.8%	79%
Other subsidiaries, export, etc	18.0	18.0	0.0	4.0	+20.6%	22%	4.3	+0.1%	24%	4.2	-6.7%	23%				12.4	0.4	+3.2%	69%
<b>Prasugrel</b>	<b>not disclosed</b>	<b>not disclosed</b>	<b>-</b>	<b>3.3</b>	<b>+52.6%</b>	<b>-</b>	<b>3.2</b>	<b>+37.5%</b>	<b>-</b>	<b>3.7</b>	<b>+43.5%</b>	<b>-</b>				<b>10.2</b>	<b>3.1</b>	<b>+44.3%</b>	<b>-</b>
Effient alliance revenue (US)	not disclosed	not disclosed	-	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-				7.5	2.3	+45.1%	-
Effient alliance revenue (EU)	not disclosed	not disclosed	-	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-				2.7	0.8	+42.0%	-

## 6. Number of Employees

	Mar 2012 Results	Jun 2012 Results	Sep 2012 Results	Dec 2012 Results	Mar 2013 Results
<b>Total Number of Employees</b>	<b>31,929</b>	<b>32,522</b>	<b>32,563</b>	<b>32,456</b>	
Japan	9,308	9,435	9,338	9,318	
* Overseas	22,621	23,087	23,225	23,138	
Daiichi Sankyo Group	17,877	18,043	18,042	17,780	
* Ranbaxy Group	14,052	14,479	14,521	14,676	

\* For overseas subsidiaries with different fiscal year-ends, numbers as of Sep-end are shown in the Dec-end columns

# MEMO

(This page is intentionally left blank)

## 7. Consolidated Balance Sheets

(Billions of yen)

	Mar 2012	Dec 2012	YoY	Notes
<b>ASSETS</b>				
Current assets				
Cash and time deposits	128.9	141.5	12.6	PBT +85.4 Bn, Depreciation +30.4 Bn Net purchase and acquisitions of proceeds from sales of non-current assets -62.2 Bn Dividend paid -42.3 Bn, Decrease in loans payable -24.3 Bn, Income taxes paid -22.4 Bn
Trade notes and accounts receivable	228.5	246.9	18.4	
Marketable securities	191.3	158.2	-33.2	
Inventories	169.7	172.4	2.8	
Deferred tax assets	94.0	95.0	1.0	
Other current assets	51.3	51.8	0.5	
Allowance for doubtful accounts	-2.2	-2.1	0.0	
Total current assets	861.5	863.7	2.2	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	129.3	136.2	6.9	
Machinery, equipment and vehicles, net	48.1	54.2	6.2	
Land	35.7	35.4	-0.3	
Construction in progress	33.7	49.0	15.4	
Other, net	14.5	16.7	2.2	
Total property, plant and equipment	261.2	291.5	30.2	Newly added: Kitasato Daiichi Sankyo Vaccine (KDSV) +22.1 Bn, Daiichi Sankyo +10.7 Bn
Intangible assets				
Goodwill, net	82.7	74.1	-8.7	
Other intangible assets, net	150.5	140.7	-9.9	
Total intangible assets	233.3	214.8	-18.5	
Investments and other assets				
Investment securities	104.6	106.0	1.5	
Deferred tax assets	43.2	41.7	-1.5	
Other	15.0	16.5	1.6	
Allowance for doubtful accounts	-0.3	-0.6	-0.2	
Total investments and other assets	162.4	163.7	1.3	
Total non-current assets	656.9	670.0	13.0	
<b>Total assets</b>	<b>1,518.5</b>	<b>1,533.7</b>	<b>15.2</b>	

(Billions of yen)

	Mar 2012	Dec 2012	YoY	Notes
<b>LIABILITIES</b>				
Current liabilities				
Trade notes and accounts payable	61.8	67.2	5.4	
Short-term loans payable	71.1	63.4	-7.6	
Income taxes payable	5.3	9.2	3.9	
Allowance for sales returns	0.6	3.6	3.0	
Allowance for sales rebates	2.9	2.2	-0.7	
Provision for loss on disaster	0.8	0.0	-0.7	
Provision for settlement expenses	39.1	38.9	-0.3	
Other current liabilities	213.3	214.9	1.5	
<b>Total current liabilities</b>	<b>395.0</b>	<b>399.4</b>	<b>4.4</b>	
Long-term liabilities				
Bonds payable	100.0	100.0	0.0	
Long-term loans payable	104.0	87.1	-16.9	
Deferred tax liabilities	52.1	51.2	-0.9	
Accrued employees' severance and retirement benefits	10.1	12.4	2.3	
Accrued directors' severance and retirement benefits	0.2	0.2	0.0	
Provision for environment measures	1.2	0.0	-1.2	
Other long-term liabilities	23.2	21.2	-2.0	
<b>Total long-term liabilities</b>	<b>290.8</b>	<b>272.1</b>	<b>-18.6</b>	
<b>Total liabilities</b>	<b>685.7</b>	<b>671.6</b>	<b>-14.2</b>	
<b>NET ASSETS</b>				
Shareholders' equity				
Common stock	50.0	50.0	0.0	
Capital surplus	105.2	105.2	0.0	
Retained earnings	742.4	751.6	9.2	Net income +51.5 Bn, Dividend paid -42.2 Bn
Treasury stock, at cost	-14.6	-14.5	0.1	
<b>Total shareholders' equity</b>	<b>883.0</b>	<b>892.3</b>	<b>9.3</b>	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	22.3	23.3	1.0	
Deferred gains or losses on hedges	0.2	0.9	0.7	
Foreign currency translation adjustments	-100.6	-87.2	13.4	Increase in net assets of overseas subsidiaries on a JPY basis +13.4 Bn
<b>Total accumulated other comprehensive income</b>	<b>-78.1</b>	<b>-63.0</b>	<b>15.1</b>	
Subscription rights to shares	3.5	4.0	0.5	
Minority interests	24.3	28.7	4.4	Ranbaxy +4.3 Bn
<b>Total net assets</b>	<b>832.7</b>	<b>862.1</b>	<b>29.4</b>	
<b>Total liabilities and net assets</b>	<b>1,518.5</b>	<b>1,533.7</b>	<b>15.2</b>	

## 8. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2011 Q3 Results	FY2012 Q3 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	40.4	85.4	45.0	
Depreciation and amortization of goodwill	41.9	38.7	-3.2	
Increase/decrease in trade receivable and payable	-18.4	-32.6	-14.2	
Other, net	29.4	12.1	-17.4	
Income taxes paid	-23.2	-22.4	0.8	
Net cash provided by operating activities	70.1	81.1	11.0	
Cash flows from investing activities				
Net (increase) decrease in short-term investments	32.3	-43.8	-76.1	
(Acquisition of) proceeds from sales of non-current assets	-34.3	-62.2	-27.9	
Acquisition of investments in subsidiaries	-71.3	-0.0	71.2	FY2011: Plexikon Inc -71.2 Bn
Other, net	-23.4	19.6	43.0	FY2011: Kitasato Daiichi Sankyo Vaccine (KDSV) - Payment for transfer of business -16.1 Bn
Net cash used in investing activities	-96.7	-86.5	10.2	
Cash flows from financing activities				
Net increase (decrease) in loans payable	7.2	-24.3	-31.5	
Redemption of bonds	-46.6	—	46.6	FY2011: Redemption of Ranbaxy's foreign currency convertible bond
Dividends paid	-42.8	-42.3	0.6	
Other, net	11.4	-0.1	-11.4	FY2011: Investment in KDSV from The Kitasato Institute
Net cash used in financing activities	-70.9	-66.6	4.2	
Effect of exchange rate changes on cash and cash equivalents	-10.5	3.6	14.2	
Net increase (decrease) in cash and cash equivalents	-108.0	-68.4	39.6	
Cash and cash equivalents, beginning of period	302.4	212.7	-89.7	
Cash and cash equivalents, at end of period	194.4	144.3	-50.1	

## 9. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
<b>Japan Company (domestic sales)</b>					
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo	Kowa
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memory	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	AstraZeneca
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe
<b>Daiichi Sankyo, Inc. (US)</b>					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
<b>Luitpold Pharmaceuticals, Inc. (US)</b>					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
<b>Daiichi Sankyo Europe GmbH</b>					
Olmesartan					
Olmetec	olmesartan		2002		
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly

## 10. Major R&D Pipeline (Innovative pharmaceuticals)

### ◆ Filed

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP	Filed Filed in Mar 2012
<p>The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors.</p>					
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP	Filed Filed in Nov 2012
<p>The long-acting neuraminidase inhibitor which was developed and produced by Daiichi Sankyo. This is an inhalant that will act directly on the pulmonary and tracheal sites of infection. Launched in Japan in October 2010 as treatment for influenza A and influenza B viruses.</p>					



◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks	
DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	Global	P3	Study to be completed in FY2012
			Venous thromboembolism (VTE)	Global	P3	Study to be completed in FY2012
CS-747	prasugrel	Anti-platelet agent	Acute coronary syndrome(ACS-PCI)	JP	P3	Application to be expected in FY2013
			Elective PCI	JP	P3	Applicaition to be expected in FY2013
			Ischemic Stroke	JP	P3	Study to be completed in FY2014
			Sickle cell disease	US	P2	
AMG 162	denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	
			Rheumatoid arthritis	JP	P2	
			Giant cell tumor	JP	P2	
DR-3355	levofloxacin	New quinolone	Anti-infection	JP	P3	
CS-3150	-	MR antagonist	Hypertension	JP	P2	
DS-7250	-	DGAT1 inhibitor	Diabetes	JP	P2	
			Diabetes, Obesity	US/EU	P1	
ARQ 197	tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P2	
			Colorectal cancer	US/EU	P2	
CS-1008	tigatuzumab	Anti-DR5 antibody	Hepatocellular cancer	Global	P2	
DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P2	
			Non small cell lung cancer	JP	P2	
			Esophageal cancer	JP	P1	
CS-7017	efatutazone	PPAR-gamma agonist	Non small cell lung cancer	US/EU	P2	
			Colorectal cancer	US/EU	P2	
			Non small cell lung cancer	Asia	P1	
			Colorectal cancer	JP	P1	
U3-1287	patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2	
			Non small cell lung cancer	JP	P1	
			Breast cancer	US	P2	
			Breast cancer	JP	P1	
PLX4032	vemurafenib	BRAF inhibitor	Throid cancer	US/EU	P2	
PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma	US	P2	
			Acute myeloid leukemia	US	P2	
			Glioblastoma	US	P2	
			Prostate Caner	US	P2	

◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
DS-5565	-	α2δ ligand	Chronic pain	Global	P2
SUN13837	-	Modulator of bFGF signaling system	Spinal cord injury	US/EU	P2
ASB17061	-	Chymase inhibitor	Atopic Dermatitis	US	P2
DS-7309	-	Glucokinase activator	Diabetes	-	P1
DS-6930	-	Selective PPAR-gamma modulator	Diabetes	-	P1
DS-8500	-	GPR119 agonist	Diabetes	-	P1
DS-1442	-	CETP inhibitor	Dyslipidemia	-	P1
U3-1565	-	Anti-HB-EGF antibody	Solid cancer	US/JP	P1
DS-2248	-	HSP90 inhibitor	Solid cancer	US	P1
DS-7423	-	PI3K/mTOR inhibitor	Solid cancer	US/JP	P1
ARQ 092	-	Akt inhibitor	Solid cancer	US	P1
DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza	US/EU	P1
DS-8587	-	Topoisomerase inhibitor	Anti-bacterial	-	P1
CS-4771	-	TLR4 inhibitor	Anti-sepsis	-	P1
PLX5622	-	FMS kinase inhibitor	Rheumatoid arthritis	-	P1
CS-0777	-	S1P receptor modulator	Immunomodulator	-	P1
DS-7113	hydromorphone	opioid mu-receptor regulator	Narcotic analgesic	-	P1

◆ Change of stage from announcement in Oct 2012

Project code Number	Generic Name	Class	Target indication	Stage	
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP	Filed
ASB17061	-	Chymase inhibitor	Atopic Dermatitis	US	P2

◆ Major R&D Pipeline Table

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	<p><b>DS-7309</b> (Anti-diabetes / Glucokinase activator)</p> <p><b>DS-6930</b> (Anti-diabetes / Selective PPAR-gamma modulator)</p> <p><b>DS-8500</b> (Anti-diabetes / GPR119 agonist)</p> <p><b>DS-1442</b> (Dyslipidemia / CETP inhibitor)</p>	<p><b>CS-747 (US)</b> (prasugrel / Sickle cell disease / anti-platelet agent)</p> <p><b>CS-3150 (JP)</b> (Anti-hypertension / MR antagonist)</p> <p><b>DS-7250 (JP)</b> (Anti-diabetes / DGAT1 inhibitor)</p>	<p><b>DU-176b (Global)</b> (edoxaban / AF / oral factor Xa inhibitor)</p> <p><b>DU-176b (Global)</b> (edoxaban / VTE / oral factor Xa inhibitor)</p> <p><b>CS-747 (JP)</b> (prasugrel / PCI / anti-platelet agent)</p> <p><b>CS-747 (JP)</b> (prasugrel / ischemic stroke / anti-platelet agent)</p>	
Oncology	<p><b>U3-1565 (US/JP)</b> (Anti-HB-EGF antibody)</p> <p><b>DS-2248 (US)</b> (HSP90 inhibitor)</p> <p><b>DS-7423 (US/JP)</b> (PI3K/mTOR inhibitor)</p> <p><b>ARQ 092 (US)</b> (Akt inhibitor)</p> <p><b>DS-3078 (US/EU)</b> (mTOR inhibitor)</p>	<p><b>ARQ 197 (US/EU)</b> (tivantinib / MET inhibitor)</p> <p><b>CS-1008 (Global)</b> (tigatuzumab / anti-DR5 antibody)</p> <p><b>DE-766 (JP)</b> (nimotuzumab / anti-EGFR antibody)</p> <p><b>CS-7017 (US/EU)</b> (efatutazone / PPARγ agonist)</p> <p><b>U3-1287 (US/EU)</b> (patritumab / anti-HER3 antibody)</p> <p><b>PLX4032 (US/EU)</b> (vemurafenib / BRAF inhibitor)</p> <p><b>PLX3397 (US)</b> (Fms/Kit/Flt3-ITD inhibitor)</p>	<p><b>AMG 162 (JP)</b> (denosumab / breast cancer adjuvant / anti-RANKL antibody)</p>	
Others	<p><b>CS-8958 (US/EU)</b> (laninamivir / anti-influenza / Outlicensing with Biota)</p> <p><b>DS-8587</b> (Anti-bacterial / Topoisomerase inhibitor )</p> <p><b>CS-4771</b> (Anti-sepsis / TLR4 inhibitor)</p> <p><b>PLX5622</b> (Rheumatoid arthritis / FMS kinase inhibitor)</p> <p><b>CS-0777</b> (Immunomodulator / S1P receptor modulator)</p> <p></p> <p><b>DS-7113</b> (hydromorphone / Narcotic analgesic / opioid mu-receptor regulator )</p>	<p><b>AMG 162 (JP)</b> (denosumab / Rheumatoid arthritis / anti-RANKL antibody)</p> <p><b>DS-5565 (Global)</b> (Chronic pain / α2δ ligand)</p> <p><b>SUN13837 (US/EU)</b> (Spinal cord injury / Modulator of bFGF signaling system)</p> <p><b>ASB17061 (US)</b> (Atopic Dermatitis / chymase inhibitor)</p>	<p></p> <p><b>DR-3355 (JP)</b> (levofloxacin / anti-infection / New quinolone)</p>	<p><b>CS-8958 (JP)</b> (laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)</p> <p><b>AMG 162 (JP)</b> (denosumab / osteoporosis / anti-RANKL antibody)</p>

**1. Summary of Consolidated Income Statement (FY2011)**

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>231.7</b>	<b>-9.7%</b>	<b>100%</b>	<b>224.4</b>	<b>-7.5%</b>	<b>100%</b>	<b>240.4</b>	<b>-3.5%</b>	<b>100%</b>	<b>242.3</b>	<b>+10.5%</b>	<b>100%</b>	<b>938.7</b>	<b>-28.7</b>	<b>-3.0%</b>
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
<b>Operating Income</b>	<b>19%</b>	<b>43.5</b>	<b>-28.8%</b>	<b>8%</b>	<b>18.7</b>	<b>-35.6%</b>	<b>12%</b>	<b>29.7</b>	<b>-2.8%</b>	<b>3%</b>	<b>6.3</b>	<b>+318.5%</b>	<b>10%</b>	<b>98.2</b>	<b>-23.9</b>	<b>-19.6%</b>
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
<b>Ordinary Income</b>	<b>19%</b>	<b>44.8</b>	<b>-36.0%</b>	<b>10%</b>	<b>21.5</b>	<b>-4.6%</b>	<b>8%</b>	<b>20.1</b>	<b>-47.1%</b>	<b>-4%</b>	<b>-10.2</b>	<b>-</b>	<b>8%</b>	<b>76.2</b>	<b>-55.5</b>	<b>-42.2%</b>
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
<b>Net Income</b>	<b>11%</b>	<b>25.3</b>	<b>-23.5%</b>	<b>5%</b>	<b>11.7</b>	<b>-38.5%</b>	<b>-8%</b>	<b>-19.5</b>	<b>-</b>	<b>-3%</b>	<b>-7.2</b>	<b>-</b>	<b>1%</b>	<b>10.4</b>	<b>-59.7</b>	<b>-85.2%</b>
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

**2. Currency Rate (FY2011)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20

## 3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
<b>Net sales</b>	<b>100%</b>	<b>192.0</b>	<b>-4.8%</b>	<b>100%</b>	<b>186.0</b>	<b>-6.4%</b>	<b>100%</b>	<b>205.0</b>	<b>-4.1%</b>	<b>100%</b>	<b>180.6</b>	<b>-0.4%</b>	<b>100%</b>	<b>763.6</b>	<b>-31.8</b>	<b>-4.0%</b>
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
<b>Operating Income</b>	<b>21%</b>	<b>39.6</b>	<b>-8.5%</b>	<b>10%</b>	<b>18.7</b>	<b>-19.4%</b>	<b>15%</b>	<b>30.2</b>	<b>-2.9%</b>	<b>-3%</b>	<b>-4.8</b>	<b>-</b>	<b>11%</b>	<b>83.7</b>	<b>-16.1</b>	<b>-16.2%</b>
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
<b>Ordinary Income</b>	<b>22%</b>	<b>41.6</b>	<b>-4.2%</b>	<b>10%</b>	<b>19.0</b>	<b>-17.8%</b>	<b>15%</b>	<b>31.1</b>	<b>-7.9%</b>	<b>-3%</b>	<b>-4.6</b>	<b>-</b>	<b>11%</b>	<b>87.0</b>	<b>-13.0</b>	<b>-13.0%</b>
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
<b>Net Income</b>	<b>12%</b>	<b>22.9</b>	<b>+2.5%</b>	<b>6%</b>	<b>10.7</b>	<b>-41.9%</b>	<b>5%</b>	<b>11.0</b>	<b>-57.5%</b>	<b>-4%</b>	<b>-7.2</b>	<b>-</b>	<b>5%</b>	<b>37.4</b>	<b>-21.4</b>	<b>-36.4%</b>
<b>Ranbaxy Group</b>																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
<b>Net sales</b>	<b>100%</b>	<b>40.0</b>	<b>-27.1%</b>	<b>100%</b>	<b>38.6</b>	<b>-11.7%</b>	<b>100%</b>	<b>35.9</b>	<b>+1.1%</b>	<b>100%</b>	<b>62.0</b>	<b>+59.5%</b>	<b>100%</b>	<b>176.6</b>	<b>3.5</b>	<b>+2.0%</b>
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
<b>Operating Income</b>	<b>13%</b>	<b>5.3</b>	<b>-72.7%</b>	<b>4%</b>	<b>1.7</b>	<b>-74.9%</b>	<b>2%</b>	<b>0.9</b>	<b>+34.5%</b>	<b>20%</b>	<b>12.6</b>	<b>+998.6%</b>	<b>12%</b>	<b>20.4</b>	<b>-7.3</b>	<b>-26.4%</b>
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
<b>Ordinary Income</b>	<b>14%</b>	<b>5.8</b>	<b>-79.6%</b>	<b>11%</b>	<b>4.2</b>	<b>+353.5%</b>	<b>-26%</b>	<b>-9.5</b>	<b>-</b>	<b>-6%</b>	<b>-3.9</b>	<b>-</b>	<b>-2%</b>	<b>-3.4</b>	<b>-43.4</b>	<b>-</b>
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
<b>Net Income</b>	<b>17%</b>	<b>6.9</b>	<b>-62.7%</b>	<b>9%</b>	<b>3.5</b>	<b>-22.7%</b>	<b>-16%</b>	<b>-5.6</b>	<b>-</b>	<b>-62%</b>	<b>-38.5</b>	<b>-</b>	<b>-19%</b>	<b>-33.7</b>	<b>-57.1</b>	<b>-</b>
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		<b>-0.3</b>			<b>-0.3</b>			<b>-0.6</b>			<b>-0.4</b>			<b>-1.5</b>		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
<b>Operating Income</b>		<b>-1.4</b>			<b>-1.6</b>			<b>-1.3</b>			<b>-1.5</b>			<b>-5.9</b>		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
<b>Ordinary Income</b>		<b>-2.5</b>			<b>-1.7</b>			<b>-1.5</b>			<b>-1.7</b>			<b>-7.3</b>		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
<b>Net Income</b>		<b>-4.4</b>			<b>-2.4</b>			<b>-24.9</b>			<b>38.5</b>			<b>6.7</b>		

**4. Sales by Business Units (FY2011)**

JPY Bn	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
<b>Consolidated Net Sales</b>	<b>231.7</b>	<b>-9.7%</b>	<b>24%</b>	<b>224.4</b>	<b>-7.5%</b>	<b>23%</b>	<b>240.4</b>	<b>-3.5%</b>	<b>25%</b>	<b>242.3</b>	<b>+10.5%</b>	<b>25%</b>	<b>938.7</b>	<b>-3.0%</b>	<b>97%</b>
<b>Japan Company (domestic sales)</b>	<b>100.4</b>	<b>-4.6%</b>	<b>23%</b>	<b>100.5</b>	<b>-2.4%</b>	<b>23%</b>	<b>113.9</b>	<b>-2.4%</b>	<b>26%</b>	<b>94.9</b>	<b>+4.3%</b>	<b>22%</b>	<b>409.8</b>	<b>-1.5%</b>	<b>94%</b>
Olmotec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Mearny	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.7</b>	<b>+4.9%</b>	<b>20%</b>	<b>12.7</b>	<b>+8.2%</b>	<b>26%</b>	<b>13.7</b>	<b>+4.1%</b>	<b>28%</b>	<b>9.7</b>	<b>-8.5%</b>	<b>20%</b>	<b>45.9</b>	<b>+2.3%</b>	<b>94%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>34.6</b>	<b>+3.2%</b>	<b>27%</b>	<b>29.7</b>	<b>-12.4%</b>	<b>23%</b>	<b>30.1</b>	<b>-13.0%</b>	<b>23%</b>	<b>32.6</b>	<b>+15.0%</b>	<b>25%</b>	<b>127.1</b>	<b>-2.6%</b>	<b>98%</b>
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>12.7</b>	<b>-13.6%</b>	<b>26%</b>	<b>9.3</b>	<b>-31.7%</b>	<b>19%</b>	<b>15.0</b>	<b>+31.0%</b>	<b>31%</b>	<b>7.6</b>	<b>-45.6%</b>	<b>16%</b>	<b>44.7</b>	<b>-17.0%</b>	<b>91%</b>
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
<b>Daiichi Sankyo Europe GmbH</b>	<b>16.9</b>	<b>+14.0%</b>	<b>22%</b>	<b>16.9</b>	<b>+2.0%</b>	<b>22%</b>	<b>17.4</b>	<b>-4.3%</b>	<b>23%</b>	<b>19.1</b>	<b>+13.0%</b>	<b>25%</b>	<b>70.2</b>	<b>+5.7%</b>	<b>91%</b>
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmotec/Olmotec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
<b>Asia, South and Central America (ASCA)</b>	<b>6.5</b>	<b>+8.7%</b>	<b>22%</b>	<b>7.3</b>	<b>+3.8%</b>	<b>24%</b>	<b>6.9</b>	<b>+2.0%</b>	<b>23%</b>	<b>7.8</b>	<b>+2.8%</b>	<b>26%</b>	<b>28.6</b>	<b>+4.1%</b>	<b>95%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
<b>Ranbaxy Laboratories Limited</b>	<b>39.8</b>	<b>-27.5%</b>	<b>25%</b>	<b>38.4</b>	<b>-12.0%</b>	<b>24%</b>	<b>35.7</b>	<b>+0.6%</b>	<b>22%</b>	<b>61.6</b>	<b>+62.3%</b>	<b>38%</b>	<b>175.5</b>	<b>+2.1%</b>	<b>108%</b>
<b>Others</b>	<b>11.1</b>	<b>-38.7%</b>	<b>29%</b>	<b>9.5</b>	<b>-25.9%</b>	<b>25%</b>	<b>7.5</b>	<b>-40.5%</b>	<b>20%</b>	<b>8.8</b>	<b>-31.2%</b>	<b>23%</b>	<b>36.9</b>	<b>-34.5%</b>	<b>97%</b>
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

**[Reference] Sales in Local Currency**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
<b>Daiichi Sankyo, Inc. (US)</b>	<b>424</b>	<b>+16.1%</b>	<b>27%</b>	<b>382</b>	<b>-2.9%</b>	<b>24%</b>	<b>390</b>	<b>-7.5%</b>	<b>25%</b>	<b>412.0</b>	<b>+20.3%</b>	<b>26%</b>	<b>1,608</b>	<b>+5.6%</b>	<b>103%</b>
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>156</b>	<b>-2.8%</b>	<b>26%</b>	<b>121</b>	<b>-24.2%</b>	<b>21%</b>	<b>193</b>	<b>+36.4%</b>	<b>33%</b>	<b>96.0</b>	<b>-42.8%</b>	<b>16%</b>	<b>566</b>	<b>-10.0%</b>	<b>96%</b>
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
<b>Daiichi Sankyo Europe GmbH</b>	<b>144</b>	<b>+13.6%</b>	<b>21%</b>	<b>153</b>	<b>+2.7%</b>	<b>23%</b>	<b>165</b>	<b>+2.5%</b>	<b>25%</b>	<b>182.0</b>	<b>+21.5%</b>	<b>27%</b>	<b>644</b>	<b>+9.8%</b>	<b>96%</b>
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
<b>Ranbaxy Laboratories Limited</b>	<b>22</b>	<b>-21.5%</b>	<b>26%</b>	<b>21</b>	<b>-1.5%</b>	<b>25%</b>	<b>21</b>	<b>+8.0%</b>	<b>25%</b>	<b>38.0</b>	<b>+82.4%</b>	<b>45%</b>	<b>101</b>	<b>+13.9%</b>	<b>119%</b>

**5. Sales of Global Products (FY2011)**

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
<b>Olmesartan</b>	<b>63.3</b>	<b>+5.2%</b>	<b>24%</b>	<b>60.4</b>	<b>-1.6%</b>	<b>22%</b>	<b>64.2</b>	<b>-2.3%</b>	<b>24%</b>	<b>61.7</b>	<b>+13.9%</b>	<b>23%</b>	<b>249.7</b>	<b>+3.4%</b>	<b>93%</b>
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
<b>Levofloxacin</b>	<b>13.5</b>	<b>-20.2%</b>	<b>26%</b>	<b>12.8</b>	<b>-24.1%</b>	<b>24%</b>	<b>13.9</b>	<b>-23.3%</b>	<b>26%</b>	<b>12.2</b>	<b>-29.1%</b>	<b>23%</b>	<b>52.4</b>	<b>-24.2%</b>	<b>99%</b>
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
<b>Pravastatin</b>	<b>10.2</b>	<b>-13.9%</b>	<b>27%</b>	<b>10.0</b>	<b>-15.5%</b>	<b>26%</b>	<b>10.6</b>	<b>-8.6%</b>	<b>28%</b>	<b>8.4</b>	<b>-12.6%</b>	<b>22%</b>	<b>39.2</b>	<b>-12.7%</b>	<b>103%</b>
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
<b>Prasugrel</b>	<b>2.2</b>	<b>+176.5%</b>	<b>-</b>	<b>2.3</b>	<b>+134.2%</b>	<b>-</b>	<b>2.6</b>	<b>+72.6%</b>	<b>-</b>	<b>3.8</b>	<b>+94.3%</b>	<b>-</b>	<b>10.9</b>	<b>+108.2%</b>	<b>-</b>
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Efient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-

n

**1. Summary of Consolidated Income Statement (FY2010)**

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>256.4</b>	<b>+12.9%</b>	<b>100%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>100%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>100%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>100%</b>	<b>967.4</b>	<b>15.3</b>	<b>+1.6%</b>
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
<b>Operating Income</b>	<b>24%</b>	<b>61.1</b>	<b>+128.1%</b>	<b>12%</b>	<b>29.0</b>	<b>+20.6%</b>	<b>12%</b>	<b>30.5</b>	<b>-22.2%</b>	<b>1%</b>	<b>1.5</b>	<b>-72.2%</b>	<b>13%</b>	<b>122.1</b>	<b>26.6</b>	<b>+27.9%</b>
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
<b>Ordinary Income</b>	<b>27%</b>	<b>70.1</b>	<b>+877.7%</b>	<b>9%</b>	<b>22.6</b>	<b>-50.0%</b>	<b>15%</b>	<b>38.0</b>	<b>-1.1%</b>	<b>1%</b>	<b>1.2</b>	<b>-90.7%</b>	<b>14%</b>	<b>131.8</b>	<b>28.6</b>	<b>+27.8%</b>
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
<b>Net Income</b>	<b>13%</b>	<b>33.1</b>	<b>-</b>	<b>8%</b>	<b>19.1</b>	<b>-24.1%</b>	<b>11%</b>	<b>27.5</b>	<b>+33.8%</b>	<b>-4%</b>	<b>-9.5</b>	<b>-</b>	<b>7%</b>	<b>70.1</b>	<b>28.3</b>	<b>+67.5%</b>
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

**2. Currency Rate (FY2010)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02



**3. Segment Information (FY2010)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	<b>201.6</b>	<b>+2.1%</b>	100%	<b>198.8</b>	<b>-4.0%</b>	100%	<b>213.7</b>	<b>-2.4%</b>	100%	<b>181.3</b>	<b>-0.3%</b>	100%	<b>795.5</b>	<b>-10.0</b>	<b>-1.2%</b>
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
<b>Operating Income</b>	22%	<b>43.3</b>	<b>+44.0%</b>	12%	<b>23.2</b>	<b>-11.6%</b>	15%	<b>31.1</b>	<b>-20.6%</b>	1%	<b>2.3</b>	<b>-1422.3%</b>	13%	<b>99.8</b>	<b>4.6</b>	<b>+4.8%</b>
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
<b>Ordinary Income</b>	22%	<b>43.4</b>	<b>+34.8%</b>	12%	<b>23.1</b>	<b>-12.6%</b>	16%	<b>33.7</b>	<b>-12.9%</b>	0%	<b>-0.2</b>	-	13%	<b>100.0</b>	<b>3.8</b>	<b>+4.0%</b>
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
<b>Net Income</b>	11%	<b>22.3</b>	<b>+122.8%</b>	9%	<b>18.3</b>	<b>+39.4%</b>	12%	<b>26.0</b>	<b>+30.0%</b>	-4%	<b>-7.8</b>	-	7%	<b>58.8</b>	<b>23.9</b>	<b>+68.6%</b>
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	<b>54.9</b>	<b>+84.9%</b>	100%	<b>43.8</b>	<b>+20.1%</b>	100%	<b>35.5</b>	<b>-1.4%</b>	100%	<b>38.9</b>	<b>-12.6%</b>	100%	<b>173.1</b>	<b>26.4</b>	<b>+18.0%</b>
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
<b>Operating Income</b>	35%	<b>19.3</b>	<b>-1171.9%</b>	15%	<b>6.6</b>	<b>-1214.7%</b>	2%	<b>0.6</b>	<b>-60.0%</b>	3%	<b>1.1</b>	<b>-83.9%</b>	16%	<b>27.7</b>	<b>21.4</b>	<b>+338.8%</b>
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
<b>Ordinary Income</b>	52%	<b>28.3</b>	<b>-220.1%</b>	2%	<b>0.9</b>	<b>-95.4%</b>	16%	<b>5.5</b>	<b>+374.9%</b>	14%	<b>5.3</b>	<b>-65.1%</b>	23%	<b>40.0</b>	<b>27.0</b>	<b>+207.8%</b>
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
<b>Net Income</b>	33%	<b>18.4</b>	-	10%	<b>4.5</b>	<b>-68.3%</b>	11%	<b>3.8</b>	-	-9%	<b>-3.3</b>	-	14%	<b>23.3</b>	<b>19.1</b>	<b>+456.4%</b>
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		<b>-0.1</b>			<b>-0.1</b>			<b>-0.1</b>			<b>-0.9</b>			<b>-1.2</b>		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
<b>Operating Income</b>		<b>-1.5</b>			<b>-0.7</b>			<b>-1.2</b>			<b>-1.9</b>			<b>-5.4</b>		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
<b>Ordinary Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.3</b>			<b>-3.9</b>			<b>-8.2</b>		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
<b>Net Income</b>		<b>-7.6</b>			<b>-3.8</b>			<b>-2.2</b>			<b>1.6</b>			<b>-12.0</b>		

**4. Sales by Business Units (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>256.4</b>	<b>+12.9%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>967.4</b>	<b>+1.6%</b>
<b>Japan Company (domestic sales)</b>	<b>105.3</b>	<b>+0.6%</b>	<b>103.0</b>	<b>-1.7%</b>	<b>116.8</b>	<b>-1.4%</b>	<b>91.0</b>	<b>+7.6%</b>	<b>416.0</b>	<b>+0.9%</b>
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.3</b>	<b>-2.7%</b>	<b>11.7</b>	<b>-12.9%</b>	<b>13.2</b>	<b>+9.1%</b>	<b>10.6</b>	<b>+23.2%</b>	<b>44.8</b>	<b>+2.6%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.6</b>	<b>+1.7%</b>	<b>33.9</b>	<b>+1.2%</b>	<b>34.6</b>	<b>+0.6%</b>	<b>28.4</b>	<b>-11.6%</b>	<b>130.5</b>	<b>-1.9%</b>
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>14.7</b>	<b>+10.4%</b>	<b>13.7</b>	<b>+1.3%</b>	<b>11.5</b>	<b>-8.5%</b>	<b>14.0</b>	<b>+10.5%</b>	<b>53.9</b>	<b>+3.5%</b>
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
<b>Daiichi Sankyo Europe GmbH</b>	<b>14.8</b>	<b>-14.6%</b>	<b>16.6</b>	<b>-10.0%</b>	<b>18.1</b>	<b>-5.0%</b>	<b>16.9</b>	<b>-17.2%</b>	<b>66.4</b>	<b>-11.7%</b>
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
<b>Asia, South and Central America (ASCA)</b>	<b>5.9</b>	<b>+12.7%</b>	<b>7.1</b>	<b>+12.8%</b>	<b>6.8</b>	<b>+3.3%</b>	<b>7.6</b>	<b>-0.4%</b>	<b>27.4</b>	<b>+6.4%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
<b>Ranbaxy Laboratories Limited</b>	<b>54.8</b>	<b>+84.7%</b>	<b>43.7</b>	<b>+19.9%</b>	<b>35.4</b>	<b>-1.6%</b>	<b>38.0</b>	<b>-14.5%</b>	<b>171.9</b>	<b>+17.3%</b>
<b>Others</b>	<b>18.0</b>	<b>+25.6%</b>	<b>12.8</b>	<b>-25.1%</b>	<b>12.7</b>	<b>-20.2%</b>	<b>12.8</b>	<b>-20.0%</b>	<b>56.3</b>	<b>-11.1%</b>
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

**[Reference] Sales in Local Currency (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daiichi Sankyo, Inc. (US)</b>	<b>365</b>	<b>+7.6%</b>	<b>394</b>	<b>+10.2%</b>	<b>422</b>	<b>+10.3%</b>	<b>342</b>	<b>-3.3%</b>	<b>1,522</b>	<b>+6.3%</b>
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>160</b>	<b>+16.7%</b>	<b>159</b>	<b>+10.6%</b>	<b>142</b>	<b>+1.2%</b>	<b>168</b>	<b>+20.1%</b>	<b>629</b>	<b>+12.1%</b>
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
<b>Daiichi Sankyo Europe GmbH</b>	<b>126</b>	<b>-3.2%</b>	<b>149</b>	<b>+8.3%</b>	<b>161</b>	<b>+12.1%</b>	<b>150</b>	<b>-7.0%</b>	<b>587</b>	<b>+2.3%</b>
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>28</b>	<b>+76.3%</b>	<b>21</b>	<b>+17.1%</b>	<b>19</b>	<b>+4.6%</b>	<b>21</b>	<b>-9.0%</b>	<b>89</b>	<b>+18.5%</b>

**5. Sales of Global Products (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmesartan</b>	<b>60.2</b>	<b>+7.6%</b>	<b>61.4</b>	<b>+3.4%</b>	<b>65.7</b>	<b>+1.6%</b>	<b>54.2</b>	<b>-7.0%</b>	<b>241.5</b>	<b>+1.4%</b>
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
<b>Levofloxacin</b>	<b>17.0</b>	<b>-14.3%</b>	<b>16.9</b>	<b>-28.0%</b>	<b>18.1</b>	<b>-18.3%</b>	<b>17.2</b>	<b>-21.1%</b>	<b>69.1</b>	<b>-20.7%</b>
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
<b>Pravastatin</b>	<b>11.9</b>	<b>-19.1%</b>	<b>11.8</b>	<b>-21.5%</b>	<b>11.6</b>	<b>-21.8%</b>	<b>9.6</b>	<b>-8.3%</b>	<b>44.9</b>	<b>-18.4%</b>
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.8</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>1.5</b>	<b>-</b>	<b>2.0</b>	<b>-</b>	<b>5.2</b>	<b>+889.6%</b>
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

**1. Summary of Consolidated Income Statement (FY2009)**

JPY Bn	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>227.1</b>	<b>+11.5%</b>	<b>100%</b>	<b>243.4</b>	<b>+20.2%</b>	<b>100%</b>	<b>255.1</b>	<b>+15.3%</b>	<b>100%</b>	<b>226.4</b>	<b>+5.6%</b>	<b>100%</b>	<b>952.1</b>	<b>110.0</b>	<b>+13.1%</b>
Cost of sales	28%	62.5	+28.5%	31%	74.7	+52.5%	30%	75.4	+41.9%	29%	65.4	+2.8%	29%	278.0	63.6	+29.7%
Gross Profit	72%	164.6	+6.1%	69%	168.7	+9.8%	70%	179.7	+6.8%	71%	161.1	+6.7%	71%	674.1	46.3	+7.4%
SG&A expenses	61%	137.8	+19.8%	59%	144.6	+9.6%	55%	140.5	+6.6%	69%	155.6	-2.8%	61%	578.6	39.7	+7.4%
R&D expenses	20%	45.1	+22.2%	20%	49.0	+7.9%	19%	47.6	+1.6%	24%	55.1	-0.5%	21%	196.8	12.3	+6.6%
Other expenses	41%	92.7	+18.6%	39%	95.6	+10.5%	36%	92.9	+9.4%	44%	100.5	-4.0%	40%	381.8	27.4	+7.7%
<b>Operating Income</b>	<b>12%</b>	<b>26.8</b>	<b>-33.1%</b>	<b>10%</b>	<b>24.1</b>	<b>+11.5%</b>	<b>15%</b>	<b>39.2</b>	<b>+7.6%</b>	<b>2%</b>	<b>5.4</b>	<b>-</b>	<b>10%</b>	<b>95.5</b>	<b>6.6</b>	<b>+7.5%</b>
Non-operating income / expenses		-19.6			21.0			-0.8			7.0			7.6	41.3	
Non-operating income		3.9			10.9			4.3			9.1			28.2	15.9	
Non-operating expenses		23.5			-10.1			5.1			2.1			20.6	-25.4	
<b>Ordinary Income</b>	<b>3%</b>	<b>7.2</b>	<b>-82.5%</b>	<b>19%</b>	<b>45.1</b>	<b>+140.0%</b>	<b>15%</b>	<b>38.4</b>	<b>+14.4%</b>	<b>6%</b>	<b>12.5</b>	<b>-</b>	<b>11%</b>	<b>103.1</b>	<b>47.9</b>	<b>+86.9%</b>
Extraordinary income / losses		1.5			-0.1			-1.1			-6.1			-5.7	357.7	
Extraordinary income		2.1			0.2			1.5			2.1			5.9	2.1	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-355.6	
Income before income taxes and minority interests	4%	8.6	-78.2%	18%	45.0	+164.3%	15%	37.3	-	3%	6.4	-	10%	97.4	405.6	-
Income taxes / minority interests		15.1			19.9			16.8			3.8			55.5	148.3	
Income taxes		24.0			12.8			16.0			-2.7			50.0	129.2	
Minority interests		-8.9			7.1			0.7			6.5			5.5	19.1	
<b>Net Income</b>	<b>-3%</b>	<b>-6.4</b>	<b>-</b>	<b>10%</b>	<b>25.1</b>	<b>+182.7%</b>	<b>8%</b>	<b>20.6</b>	<b>-</b>	<b>1%</b>	<b>2.6</b>	<b>-96.8%</b>	<b>4%</b>	<b>41.9</b>	<b>257.4</b>	<b>-</b>
Effective tax rate		278%			28%			43%			-			51%		
Overseas sales ratio results		48%			50%			47%			57%			51%		

**2. Currency Rate (FY2009)**

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2009	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	97.33	95.50	93.57	92.86	92.86	-7.68
EUR/JPY (average)	132.58	133.16	133.00	131.16	131.16	-12.33
INR/JPY (average)	1.89	1.95	1.95	1.95	1.95	-0.05

**3. Segment Information (FY2009)**

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	197.4	-3.1%	100%	207.0	+2.2%	100%	219.1	-1.0%	100%	181.9	+3.4%	100%	805.5	1.9	+0.2%
Cost of sales	23%	45.4	-6.7%	26%	54.3	+10.9%	25%	55.6	+4.6%	26%	47.3	+14.6%	25%	202.6	10.5	+5.5%
Gross Profit	77%	152.0	-2.0%	74%	152.7	-0.6%	75%	163.5	-2.8%	74%	134.6	+0.0%	75%	602.8	-8.6	-1.4%
SG&A expenses	62%	122.0	+6.0%	61%	126.5	-4.2%	57%	124.3	-1.5%	74%	134.8	+3.3%	63%	507.6	3.8	+0.8%
R&D expenses	22%	43.0	+16.5%	23%	46.7	+2.8%	21%	45.2	-3.5%	28%	51.6	+12.4%	23%	186.5	11.4	+6.5%
Other expenses	40%	79.0	+1.1%	39%	79.8	-7.8%	36%	79.1	-0.3%	46%	83.2	-1.7%	40%	321.1	-7.7	-2.3%
<b>Operating Income</b>	15%	30.0	-24.9%	13%	26.2	+21.3%	18%	39.1	-6.7%	0%	-0.2	-	12%	95.2	-12.4	-11.5%
Non-operating income		2.9			2.0			1.8			0.4			7.1	-3.8	
Non-operating expenses		0.8			1.8			2.2			1.4			6.1	-13.9	
<b>Ordinary Income</b>	16%	32.2	-21.3%	13%	26.4	+40.5%	18%	38.7	-0.8%	-1%	-1.1	-	12%	96.1	-2.2	-2.3%
Extraordinary income		2.1			0.2			1.5			0.8			4.6	0.9	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-4.0	
Income before income taxes and minority interests	17%	33.6	-15.0%	13%	26.3	+54.4%	17%	37.7	+0.5%	-5%	-8.5	-	11%	89.1	2.7	+3.2%
Income taxes		23.6			13.1			17.7			-0.2			54.3	17.8	
Minority interests																
<b>Net Income</b>	5%	10.0	-60.1%	6%	13.2	+48.0%	9%	20.0	-27.9%	-5%	-8.3	-	4%	34.8	-15.1	-30.2%
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	29.7		100%	36.4		100%	36.0		100%	44.5	+15.1%	100%	146.7	108.0	
Cost of sales	58%	17.1		56%	20.4		55%	19.8		41%	18.1	-12.0%	51%	75.4	54.9	
Gross Profit	42%	12.6		44%	16.0		45%	16.2		59%	26.4	+45.8%	49%	71.2	53.1	
SG&A expenses	48%	14.4		46%	16.6		41%	14.6		43%	19.3	+10.0%	44%	64.9	47.4	
R&D expenses	7%	2.1		6%	2.3		7%	2.4		8%	3.5	+35.7%	7%	10.3	7.7	
Other expenses	41%	12.3		39%	14.3		34%	12.2		36%	15.8	+5.6%	37%	54.6	39.6	
<b>Operating Income</b>	-6%	-1.8		-2%	-0.6		4%	1.6		16%	7.1	+1119.4%	4%	6.3	5.7	
Non-operating income		1.0			9.0			2.5			8.7			21.1	19.7	
Non-operating expenses		22.7			-11.9			2.9			0.7			14.5	-11.5	
<b>Ordinary Income</b>	-79%	-23.5		56%	20.2		3%	1.2		34%	15.1	-	9%	13.0	36.9	
Extraordinary income		0.0			0.0			0.0			1.3			1.3	1.2	
Extraordinary losses								0.0			0.1			0.1	-0.2	
Income before income taxes and minority interests	-79%	-23.5		56%	20.2		3%	1.1		37%	16.4	-	10%	14.2	38.3	
Income taxes		-6.6			6.0			1.3			9.2			9.8	17.7	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.1	
<b>Net Income</b>	-57%	-16.9		39%	14.2		-1%	-0.2		16%	7.1	-	3%	4.2	20.4	
<b>Inter-segment Transactions</b>																
<b>Net sales</b>																
Cost of sales																
Gross Profit																
SG&A expenses		1.5			1.5			1.5			1.5			6.0		
R&D expenses																
Other expenses		1.5			1.5			1.5			1.5			6.0		
<b>Operating Income</b>		-1.5			-1.5			-1.5			-1.5			-6.0		
Non-operating income																
Non-operating expenses																
<b>Ordinary Income</b>		-1.5			-1.5			-1.5			-1.5			-6.0		
Extraordinary income																
Extraordinary losses																
Income before income taxes and minority interests		-1.5			-1.5			-1.5			-1.5			-6.0		
Income taxes		7.0			-6.4			-3.0			-11.8			-14.1		
Minority interests		-8.9			7.1			0.7			6.5			5.3		
<b>Net Income</b>		0.5			-2.3			0.8			3.8			2.8		

**4. Sales by Business Units (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>227.1</b>	<b>11.5%</b>	<b>243.4</b>	<b>20.2%</b>	<b>255.1</b>	<b>15.3%</b>	<b>226.4</b>	<b>5.6%</b>	<b>952.1</b>	<b>13.1%</b>
<b>Japan Company (domestic sales)</b>	<b>104.6</b>	<b>3.7%</b>	<b>104.8</b>	<b>5.3%</b>	<b>118.4</b>	<b>-1.4%</b>	<b>84.5</b>	<b>-1.9%</b>	<b>412.3</b>	<b>1.4%</b>
Olmotec	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Calblock	3.5	14.5%	3.5	18.9%	3.8	12.5%	2.9	4.7%	13.7	12.8%
Loxonin	11.2	33.0%	12.5	19.7%	13.3	16.0%	9.9	19.4%	47.0	21.4%
Cravit	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Mevalotin	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Artist	6.0	6.3%	5.9	11.3%	6.4	6.0%	5.0	1.9%	23.3	6.5%
Omnipaque	7.1	-2.0%	7.5	3.4%	7.1	-10.8%	5.5	-4.8%	27.3	-3.7%
Urief	2.2	26.6%	2.2	26.1%	2.6	19.3%	2.0	-9.9%	9.0	14.3%
Vaccines	1.3	235.0%	1.9	40.4%	8.6	22.9%	1.3	151.5%	13.1	41.0%
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.5</b>	<b>-6.9%</b>	<b>13.5</b>	<b>-2.1%</b>	<b>12.1</b>	<b>-8.2%</b>	<b>8.6</b>	<b>-14.1%</b>	<b>43.7</b>	<b>-7.4%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.0</b>	<b>-11.2%</b>	<b>33.5</b>	<b>5.6%</b>	<b>34.4</b>	<b>5.8%</b>	<b>32.1</b>	<b>15.2%</b>	<b>133.0</b>	<b>2.9%</b>
Olmесartan	25.1	1.5%	25.4	3.5%	26.4	5.9%	24.9	13.6%	101.7	5.9%
Benicar/Benicar HCT	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Welchol	6.9	7.0%	6.5	6.6%	7.3	10.2%	6.8	28.2%	27.5	12.4%
Effient (alliance revenue)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>13.4</b>	<b>-1.1%</b>	<b>13.5</b>	<b>-0.4%</b>	<b>12.6</b>	<b>-6.4%</b>	<b>12.7</b>	<b>18.9%</b>	<b>52.1</b>	<b>1.9%</b>
Venofer	8.0	-3.9%	8.1	-4.6%	8.0	-4.1%	8.0	17.0%	32.2	0.3%
<b>Daiichi Sankyo Europe GmbH</b>	<b>17.3</b>	<b>14.1%</b>	<b>18.4</b>	<b>-0.4%</b>	<b>19.1</b>	<b>6.1%</b>	<b>20.4</b>	<b>9.7%</b>	<b>75.2</b>	<b>7.1%</b>
Olmесartan	9.2	10.7%	11.2	7.9%	12.4	17.9%	13.5	28.3%	46.3	16.5%
Olmotec/Olmotec Plus	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
<b>Asia, South and Central America (ASCA)</b>	<b>5.3</b>	<b>0.5%</b>	<b>6.3</b>	<b>7.1%</b>	<b>6.6</b>	<b>11.7%</b>	<b>7.7</b>	<b>27.5%</b>	<b>25.8</b>	<b>12.1%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.0	-4.3%	1.1	7.6%	1.1	3.1%	0.9	1.4%	4.1	2.0%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.1	48.0%	1.3	40.2%	1.4	35.2%	1.5	34.0%	5.3	38.4%
Daiichi Sankyo Taiwan	0.9	-8.6%	0.8	-14.9%	0.7	-14.4%	0.7	-4.5%	3.1	-10.7%
Daiichi Sankyo Korea	0.8	-15.6%	0.9	-2.1%	0.9	56.8%	0.9	38.9%	3.4	13.7%
Daiichi Sankyo (Thailand)	0.2	-0.9%	0.2	-0.4%	0.2	4.2%	0.3	27.4%	0.9	7.7%
Daiichi Sankyo Brasil Farmacêutica	0.8	-25.5%	1.0	-12.7%	1.3	-7.2%	1.6	18.4%	4.7	-5.2%
Daiichi Sankyo Venezuela	0.7	35.3%	0.9	45.0%	0.8	20.7%	1.7	76.3%	4.1	47.9%
<b>Ranbaxy Laboratories Limited</b>	<b>29.7</b>	<b>-</b>	<b>36.4</b>	<b>-</b>	<b>36.0</b>	<b>-</b>	<b>44.4</b>	<b>14.9%</b>	<b>146.6</b>	<b>-</b>
<b>Others</b>	<b>14.4</b>	<b>-33.2%</b>	<b>17.1</b>	<b>-13.6%</b>	<b>15.9</b>	<b>-12.3%</b>	<b>16.0</b>	<b>-3.0%</b>	<b>63.4</b>	<b>-16.5%</b>
Levofloxacin export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Efient alliance revenue (Europe)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-

**[Reference] Sales in Local Currency (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daiichi Sankyo, Inc. (US)</b>	<b>339</b>	<b>-4.6%</b>	<b>357</b>	<b>21.7%</b>	<b>382</b>	<b>13.4%</b>	<b>354</b>	<b>18.0%</b>	<b>1,433</b>	<b>11.4%</b>
Olmесartan	258	9.0%	271	18.9%	293	13.9%	274	16.9%	1,095	14.6%
Benicar/Benicar HCT	227	1.4%	237	15.6%	253	9.7%	242	14.8%	958	10.2%
Azor	31	138.0%	34	49.3%	40	50.9%	32	35.4%	138	59.4%
Welchol	71	14.9%	69	22.8%	81	18.7%	75	31.4%	296	21.7%
Effient (alliance revenue)	-	-	10	-	2	-	-11	-	1	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>137</b>	<b>6.2%</b>	<b>144</b>	<b>14.5%</b>	<b>140</b>	<b>1.1%</b>	<b>140</b>	<b>21.4%</b>	<b>561</b>	<b>10.3%</b>
Venofer	82	3.2%	87	9.6%	89	3.3%	89	19.8%	346	8.6%
EUR Mn										
<b>Daiichi Sankyo Europe GmbH</b>	<b>131</b>	<b>40.6%</b>	<b>138</b>	<b>20.8%</b>	<b>144</b>	<b>5.9%</b>	<b>161</b>	<b>9.8%</b>	<b>574</b>	<b>17.1%</b>
Olmесartan	69	36.4%	83	30.9%	93	18.4%	106	28.1%	353	27.5%
Olmotec/Olmotec Plus	63	23.0%	74	16.7%	77	10.6%	90	17.2%	304	16.5%
Sevikar	7	-	9	-	16	77.6%	16	166.6%	48	216.5%
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>16</b>	<b>-</b>	<b>18</b>	<b>-</b>	<b>18</b>	<b>-</b>	<b>23</b>	<b>17.9%</b>	<b>75</b>	<b>-</b>

**5. Sales of Global Products (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmесartan</b>	<b>56.0</b>	<b>10.5%</b>	<b>59.4</b>	<b>10.2%</b>	<b>64.7</b>	<b>12.3%</b>	<b>58.3</b>	<b>19.0%</b>	<b>238.3</b>	<b>12.9%</b>
Olmotec (JPN)	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Benicar/Benicar HCT (US)	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor (US)	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Olmotec/Olmotec Plus (EU)	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar (EU)	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Other subsidiaries, export, etc	2.6	29.9%	3.1	-7.8%	3.7	6.2%	3.7	71.4%	13.1	19.2%
<b>Levofloxacin</b>	<b>19.8</b>	<b>-23.2%</b>	<b>23.5</b>	<b>-0.3%</b>	<b>22.1</b>	<b>-14.2%</b>	<b>21.8</b>	<b>-3.5%</b>	<b>87.2</b>	<b>-10.7%</b>
Cravit (JPN)	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Other subsidiaries	1.8	-6.4%	2.0	2.9%	2.1	14.7%	1.8	-2.2%	7.7	2.2%
<b>Pravastatin</b>	<b>14.7</b>	<b>-8.5%</b>	<b>15.0</b>	<b>-5.2%</b>	<b>14.8</b>	<b>-10.8%</b>	<b>10.5</b>	<b>-14.9%</b>	<b>55.0</b>	<b>-9.6%</b>
Mevalotin (JPN)	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Other subsidiaries, export, etc	2.3	-10.0%	2.6	-6.5%	2.0	-20.2%	2.0	-15.7%	8.8	-12.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.0</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>0.3</b>	<b>-</b>	<b>-0.7</b>	<b>-</b>	<b>0.5</b>	<b>-</b>
Effient alliance revenue (US)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Efient alliance revenue (EU)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-